Andrejak M1Genes NVaur LPoncelet PClerson PCarré A.

ABSTRACT:

The objective was to compare the compliance of hypertensive patients treated with captopril twice daily or trandolapril once daily. After a 2-week placebo period, hypertensive patients (diastolic BP 95-115 mm Hg) were randomly allocated to trandolapril 2 mg once daily or to captopril 25 mg twice daily for 6 months. Trandolapril and captopril were packed in electronic pill-boxes equipped with a microprocessor that recorded date and time of each opening (MEMS). Patients’ compliance was assessed both by standard pill-count and by electronic monitoring. Blood pressure was measured using a validated semi-automatic device at the end of the placebo period and of the treatment period. One hundred sixty-two patients entered the study. Compliance data were evaluable for 133 patients (62 in the captopril group and 71 in the trandolapril group). Treatment groups were comparable at baseline except for age (P = .046). Using electronic pill-box, overall compliance was 98.9% in the trandolapril group and 97.5% in the captopril group (P = .002). The percentage of missed doses was 2.6% in the trandolapril group and 3.3% in the captopril group (P = .06). The percentage of delayed doses was 1.8% in the trandolapril group and 11.7% in the captopril group (P = .0001). The percentage of correct dosing periods, ie, a period with only one correct recorded opening, was 94.0% in the trandolapril group and 78.1% in the captopril group (P = .0001). Results were unchanged when adjusted for age. At the end of the study, 41% of patients in the trandolapril group and 27% in the captopril group (NS) had their blood pressure normalized (systolic BP <140 and diastolic BP <90 mm Hg). In this 6-month study, the electronic pill-box allowed refined analysis of compliance of hypertensive patients. Patients’ compliance with once daily trandolapril was higher than with twice daily captopril. The between-group difference is mainly explained by an increase in delayed doses in the twice daily group.

Suscribe to our newsletter

By clicking on the link below, you will be redirected to Youtube. Third-party cookies may then be installed on your browser. These cookies are not implemented directly by the Soladis Clinical Studies site but by the site to which you connect.
Important: these cookies are subject to their own privacy policies and are in no way the responsibility of Soladis.
You can view Youtube's cookie policy by clicking on the following link: Google – Privacy & terms

  Follow Soladis on Youtube

By clicking on the link below, you will be redirected to LinkedIn. Third-party cookies may then be installed on your browser. These cookies are not implemented directly by the Soladis Clinical Studies site but by the social network site to which you connect.
These cookies are subject to their own privacy policies and are in no way the responsibility of Soladis.
You can view LinkedIn's cookie policy by clicking on the following link :  LinkedIn – Cookie Policy

Follow Soladis on LinkedIn

En cliquant sur le lien ci-dessous, vous allez être redirigé vers Youtube. Des cookies tiers peuvent alors être installés sur votre navigateur. Ces cookies ne sont pas implémentés directement par le site Soladis Clinical Studies mais par le site auquel vous vous connectez.
Important : ces cookies sont soumis à leurs propres politiques de confidentialité et ne relèvent en aucun cas de la responsabilité de Soladis.
Vous pouvez consulter la politique de Youtube en matière de cookies en cliquant sur le lien suivant : Google – Règles de confidentialité et conditions d’utilisation

  Suivre Soladis sur Youtube

En cliquant sur le lien ci-dessous, vous allez être redirigé vers LinkedIn. Des cookies tiers peuvent alors être installés sur votre navigateur. Ces cookies ne sont pas implémentés directement par le site Soladis Clinical Studies mais par le site de réseau social auquel vous vous connectez.
Ces cookies sont soumis à leurs propres politiques de confidentialité et ne relèvent en aucun cas de la responsabilité de Soladis.
Vous pouvez consulter la politique de LinkedIn en matière de cookies en cliquant sur le lien suivant : LinkedIn – Politique relative aux cookies

  Suivre Soladis sur LinkedIn